Nuvation Bio And 2 Penny Stocks To Watch

With the World Trade Organization now expecting global trade growth to more than double in 2026 on the back of heavy AI infrastructure spending, attention is drifting toward smaller US listed minnows that still keep their finances in decent shape. These low priced shares can offer exposure without leaning on heavy debt or fragile cash positions. This article walks through three such financially grounded penny stocks that may merit a closer look.

The three stocks covered below are just a sample set, and the full Financially Fit Penny Stocks screen surfaced 313 more companies with equally compelling stories that are not featured in this article. To go straight to the source and identify, filter, and analyze your own high-conviction ideas, head into the Financially Fit Penny Stocks screener.

Nuvation Bio (NUVB)

Overview: Nuvation Bio is a clinical-stage biopharmaceutical company developing targeted cancer therapies, led by IBTROZI for ROS1+ lung cancer and safusidenib for IDH1-mutant brain tumors.

Operations: The business generates about US$169.9 million from oncology development activities, with roughly US$124 million from the United States and the rest from China and Japan.

Market Cap: US$1.7b

Nuvation Bio fits the Financially Fit Penny Stocks theme by pairing a low share price with oncology programs that anchor a focused, late-stage pipeline.

"Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI."

What really matters now is how one unresolved pressure on future pricing and uptake shapes the long run payoff from that pipeline.

That pricing overhang is exactly what the full narrative for Nuvation Bio unpacks in detail, including how it could affect Nuvation Bio's long term earnings power.

OPKO Health (OPK)

Overview: OPKO Health runs BioReference diagnostic labs that generate recurring testing income, alongside a higher risk pharmaceutical pipeline spanning antibodies, vaccines, and hormone therapies.

Operations: OPKO Health records about US$313 million from Diagnostics and US$275 million from Pharmaceuticals, with roughly US$377 million sourced from the United States.

Market Cap: US$1.0b

OPKO Health plugs into the Financially Fit Penny Stocks theme through BioReference Labs, which gives this lower priced stock a services based revenue engine that is easier to underwrite than a pure early stage drug developer.

"FDA approval expanding the indication for the 4Kscore prostate cancer risk test (removing the requirement for digital rectal exam input) significantly broadens its addressable market, especially among primary care providers, supporting continued test volume growth and higher-margin revenues for the Diagnostics business."

What happens to margins and sentiment now depends on how one less visible cost and funding squeeze plays out beneath that diagnostics story.

That squeeze is the real story, and the full narrative for OPKO Health shows how it could be masking where OPKO Health’s diagnostics and pipeline might be accelerating next.

Grab Holdings (GRAB)

Overview: Grab Holdings runs a Southeast Asian superapp that connects users to transport, deliveries, and GrabFin financial services that aim to improve everyday financial health.

Operations: Grab Holdings earns about US$4.7b in annual revenue, led by Deliveries at US$2.0b and Mobility at US$1.3b, with Financial Services contributing US$430 million.

Market Cap: US$12.6b

Grab Holdings fits the Financially Fit Penny Stocks theme through GrabFin and its broader payments layer. Both push affordable credit tools and savings products directly into the same app riders and diners already use every day.

"Financial Services may eventually become Grab's second economic engine. Revenue there increased 59%, while the segment's adjusted EBITDA loss narrowed from $26 million to $15 million."

What really moves the dial from here is whether one quiet shift in cash generation keeps pace with that expanding fintech ambition.

If that shift is what you care about, the full narrative for Grab Holdings provides a view of how Grab Holdings' cash generation, fintech ambition, and risk are interacting.

Seeking Fresh Alternatives Before Others?

Markets move fast and the best breakout ideas rarely stay under the radar for long. Scan these fresh lists before the crowd and act now.

• Spot cash rich businesses holding firm while others wobble, using the curated list of solid balance sheet and fundamentals (25 results).
• Track high yield opportunities that aim to keep income flowing even when prices swing, with the focused 8 dividend fortresses.
• Explore early hardware and backbone companies that are involved in AI momentum through the targeted 92 AI infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com